IRADIMED CORP (IRMD) Q3 2025 10-Q Quarterly Report
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR IRADIMED CORP (IRMD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
IRADIMED CORP Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $21.2M for Q3 2025, up 16% YoY from $18.3M in Q3 2024; nine months revenue $61.1M, up 13% from $53.9M
- • Gross margin 78% Q3 2025 vs 77% Q3 2024; nine months margin steady at 77% both years
- • Best segment Devices revenue up 20% to $15.6M Q3 2025; worst Services revenue down 16% to $0.9M Q3 2025
- • Cash and equivalents increased to $56.5M Sep 30, 2025 from $52.2M Dec 31, 2024; operating cash flow $19.0M YTD vs $19.6M prior year
- • Management expects sufficient liquidity for next 12 months; no new capital planned but may seek debt or equity if needed
Risk Factors
- • No newly added risk factors disclosed this quarter; section continues prior risks without material updates
- • Most materially updated risk: increased regulatory expenses driven by expanded FDA requirements and ongoing post-market surveillance programs
- • Regulatory risk: compliance with FDA medical device regulations amid intensified scrutiny of MRI-compatible technologies and adherence to quality system requirements
- • Operational risk: extended sales cycles of 3-6 months and dependence on GPO agreements with 3% fees impacting U.S. hospital sales execution
- • Financial risk: revenue growth 16% YoY to $21.2M this quarter with rising operating expenses including marketing and regulatory costs
Get deeper insights on IRADIMED CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.